Cingulate Inc

Cingulate Inc. is a biopharmaceutical company that develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. Its lead product candidate, CTx-1301 (dexmethylphenidate), is in Phase 3 clinical trials for ADHD in children, adolescents, and adults. The company is also developing CTx-2103 (buspirone), which is in a formulation stage for anxiety, and plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.